Despite their therapeutic potential for a variety of conditions, including Huntington's and Parkinson's disease [18,19], spinal cord injury [20,21], ischemia/reperfusion injury [22], pulmonary fibrosis [23], and cancer [[24], [25], [26], [27], [28], [29], [30], [31]], only a few BACH1 inhibitors/degraders have been identified so far. Here, BACH1 is linked to cancer.